The marketing authorisation for Intrinsa has been withdrawn at the request of the marketing-authorisation holder.
Intrinsa : EPAR - Summary for the public (PDF/282.58 KB)
First published: 21/07/2008
Last updated: 18/06/2012
|Agency product number||
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
Sexual Dysfunctions, Psychological
|Anatomical therapeutic chemical (ATC) code||
Warner Chilcott UK Ltd.
|Date of issue of marketing authorisation valid throughout the European Union||
Old Belfast Road
25/05/2012 Intrinsa - EMEA/H/C/000634 - R/0018
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Sex hormones and modulators of the genital system
Intrinsa is indicated for the treatment of hypoactive sexual desire disorder (HSDD) in bilaterally oophorectomised and hysterectomised (surgically induced menopause) women receiving concomitant estrogen therapy.